RCM
AURA icon

Regency Capital Management’s Aura Biosciences AURA Stock Holding History

Regency Capital Management’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84M Buy
540,395
+7,900
+1% +$56.5K 1.53% 24
2026
Q1 		$3.56M Sell
532,495
-6,089
-1% -$34.9K 1.59% 21
2025
Q4 		$2.94M Sell
538,584
-74,105
-12% -$440K 1.22% 30
2025
Q3 		$3.79M Sell
612,689
-53,192
-8% -$348K 1.8% 22
2025
Q2 		$4.17M Sell
665,881
-83,601
-11% -$489K 2.19% 18
2025
Q1 		$4.39M Buy
749,482
+140,058
+23% +$1.06M 2.62% 14
2024
Q4 		$5.01M Sell
609,424
-57,887
-9% -$545K 2.71% 15
2024
Q3 		$5.95M Sell
667,311
-97,744
-13% -$838K 3.27% 13
2024
Q2 		$5.78M Sell
765,055
-20,081
-3% -$147K 3.72% 10
2024
Q1 		$6.16M Buy
785,136
+80,162
+11% +$665K 3.92% 10
2023
Q4 		$6.25M Buy
704,974
+177,996
+34% +$1.51M 4.2% 7
2023
Q3 		$4.73M Sell
526,978
-5,355
-1% -$57.6K 4.02% 9
2023
Q2 		$6.57M Sell
532,333
-11,342
-2% -$121K 5.72% 6
2023
Q1 		$5.05M Sell
543,675
-10,611
-2% -$110K 6.11% 5
2022
Q4 		$5.82M Buy
554,286
+329,732
+147% +$4.2M 6.69% 5
2022
Q3 		$4.07M Sell
224,554
-30,068
-12% -$455K 4.99% 6
2022
Q2 		$3.61M Buy
+254,622
New +$4.21M 3.88% 12

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Regency Capital Management's AURA Position: Q2 2026 in Review

Regency Capital Management increased its Aura Biosciences (AURA) stake by 1.5% in Q2 2026, buying an estimated $56.5K and bringing the position to 540,395 shares worth $3.84M. The position accounts for 1.53% of the portfolio, ranked #24.

Regency Capital Management first reported a position in AURA in Q2 2022 and has held it in 17 quarters since. The position peaked at $6.57M in Q2 2023. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Regency Capital Management held 540,395 shares of Aura Biosciences worth $3.84M as of Q2 2026.
  • Regency Capital Management bought 7,900 Aura Biosciences shares in Q2 2026, an estimated $56.5K.
  • Aura Biosciences made up 1.53% of Regency Capital Management's portfolio in Q2 2026, its #24 holding.
  • Regency Capital Management first reported a position in Aura Biosciences in Q2 2022 and has held it in 17 quarters since.
  • Regency Capital Management's Aura Biosciences position peaked at $6.57M in Q2 2023.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Regency Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.